AXBERI 40 MG / 0.4 ML
ENOXAPARIN SODIUM : 40 MG / 0.4 ML · DIN 02539985 · BAXTER CORPORATION
Health Canada status: MARKETED
What is AXBERI?
AXBERI 40 MG / 0.4 ML contains ENOXAPARIN SODIUM : 40 MG / 0.4 ML. It is listed in the Health Canada Drug Product Database under DIN 02539985, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS ; SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 15-Oct-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AXBERI used for?
Prophylaxis of DVT in surgery (orthopedic, abdominal, etc.) and medical patients; treatment of DVT with/without PE; treatment of unstable angina/non-Q-wave MI; treatment of acute STEMI.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02539985 |
|---|---|
| Brand name | AXBERI |
| Generic / active ingredient | ENOXAPARIN SODIUM : 40 MG / 0.4 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 40 MG / 0.4 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | B01AB05 ENOXAPARIN |
| Biosimilar | Yes |
| Health Canada status | MARKETED |
| Status date | 15-Oct-2024 |
How is it administered?
Subcutaneous or Intravenous (bolus) injection. Prophylaxis: 30mg q12h or 40mg daily. Treatment: 1mg/kg q12h or 1.5mg/kg daily. STEMI: 30mg IV bolus plus 1mg/kg SC, then 1mg/kg SC q12h.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Do not freeze. (Note: General LMWH standard, though specific text section 11 was not fully provided in snippet).
How is it supplied?
Pre-filled syringes with protective shield: 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 100mg/mL, 120mg/0.8mL, 150mg/mL. Packs of 10.
Contraindications
Hypersensitivity to enoxaparin, heparin or LMWH; history of HIT within 100 days; active bleeding; major clotting disorders; bacterial endocarditis; active gastric ulcer; severe hypertension.
Warnings and precautions
Risk of Spinal/Epidural Hematomas with neuraxial anesthesia. Not interchangeable with other LMWHs. Risk of hemorrhage. Use with caution in patients with history of HIT.
What can be used instead?
Other Canadian products sharing ATC code B01AB05 ENOXAPARIN. 44 of 46 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AXBERI | 100 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540045 |
| AXBERI | 30 MG / 0.3 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02539977 |
| AXBERI | 60 MG / 0.6 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540002 |
| AXBERI | 80 MG / 0.8 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540010 |
| AXBERI HP | 120 MG / 0.8 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540029 |
| AXBERI HP | 150 MG | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02540037 |
| ELONOX | 100 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02532298 |
| ELONOX | 30 MG / 0.3 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02532247 |
| ELONOX | 40 MG / 0.4 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02532255 |
| ELONOX | 60 MG / 0.6 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02532263 |
Who else supplies ENOXAPARIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ENOXAPARIN appears in 433 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.